NewLimit Raises $435M for First Human Liver Trial
Key insights
- NewLimit accumulated over $610 million across three rounds in roughly one year, an unusual capital pace for a pre-clinical longevity company.
- Founders Fund led the $435 million Series C, with Lilly Ventures' participation signaling pharmaceutical industry interest in aging as a clinical drug target.
- NewLimit plans its first human clinical trial targeting the liver, marking its transition from research-stage to clinical-stage development.
Why this matters
Lilly Ventures joining a longevity-focused Series C alongside Silicon Valley investors signals that mainstream pharmaceutical capital is beginning to treat biological aging itself as a clinical category, not just a cluster of age-related diseases. NewLimit's trajectory from a $130 million Series B to a $435 million Series C in roughly one year suggests capital markets are accelerating behind longevity biotech in ways that will reshape competitor timelines and valuations. The company's planned first human liver trial is the field's clearest near-term test of whether longevity interventions can survive the transition from preclinical research to regulated human medicine.
Summary
NewLimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong, bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, has closed a $435 million Series C at a roughly $3.1 billion valuation. Founders Fund led the round, which will finance the company's first human clinical trial targeting the liver.
This is NewLimit's third major fundraise in roughly a year, following a $130 million Series B in May 2025 and $45 million more in October 2025.
Essentially: (NewLimit, Founders Fund) are moving the longevity thesis from bench science into human trials, with Lilly Ventures joining alongside Thrive Capital, Nat Friedman, and Daniel Gross.
- $435M Series C at ~$3.1B valuation, led by Founders Fund
- Prior rounds: $130M in May 2025 and $45M in October 2025
- Trial focus is the liver; company is based in South San Francisco
Lilly Ventures' participation signals that pharmaceutical investors are beginning to treat biological aging itself as a clinical category worth backing at scale.
Potential risks and opportunities
Risks
- If Phase 1 liver trial data disappoint, NewLimit's $3.1 billion valuation faces a steep correction with Founders Fund and Thrive Capital holding large positions in a company that has not yet demonstrated human efficacy
- Three major fundraises in one year without disclosed human data may invite heightened investor scrutiny if trial timelines slip beyond the current financing runway
- Lilly Ventures' co-investor position could create conflict-of-interest complications if a Lilly-affiliated entity later pursues acquisition of NewLimit, drawing governance and pricing scrutiny
Opportunities
- Lilly Ventures' participation gives pharmaceutical operations connected to that fund an early strategic read on longevity medicine, positioning them ahead of competitors if NewLimit's liver trial succeeds
- South San Francisco-area CROs, liver-specialist clinical trial sites, and contract manufacturers stand to benefit as NewLimit deploys $435 million toward its first human study
- Competing longevity startups can use NewLimit's $3.1 billion valuation as a sector pricing anchor to justify comparable fundraises, giving the broader field a benchmark it previously lacked
What we don't know yet
- Specific mechanism of the liver medicine (small molecule, gene therapy, or cell-based approach) was not disclosed in accessible reporting
- Timeline for trial initiation and current FDA investigational new drug clearance status: not addressed in the published article
- What preclinical safety or efficacy data from the liver program convinced Lilly Ventures to co-invest alongside tech investors: not disclosed
Originally reported by statnews.com
Read the original article →Original headline: NewLimit Raises $435M Led by Founders Fund at $3.1B Valuation to Launch First Human Trial of Longevity Drug — Coinbase CEO Brian Armstrong-Founded Biotech Targets Liver Cell Age Reversal